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Patients with type 1 diabetes mellitus are associated with impairment in vitamin A metabolism. This
study evaluated whether treatment with retinoic acid, the biologically active metabolite of vitamin A, can
ameliorate diabetes. All-trans retinoic acid (atRA) was used to treat streptozotocin (STZ)-induced diabetic
mice which revealed atRA administration ameliorated blood glucose levels of diabetic mice. This hy-
perglycemic amelioration was accompanied by an increase in the amount of b cells co-expressed Pdx1
and insulin and by restoration of the vascular laminin expression. The atRA-induced production of
vascular endothelial growth factor-A from the pancreatic islets was possibly the key factor that mediated
the restoration of islet vascularity and recovery of bcell mass. Furthermore, the combination of islet
transplantation and atRA administration signiﬁcantly rescued hyperglycemia in diabetic mice. These
ﬁndings suggest that vitamin A derivatives can potentially be used as a supplementary treatment to
improve diabetes management and glycemic control.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Diabetes mellitus (DM), a syndrome of disordered metabolism,
is a major public health problem affecting 422 million people
worldwide [1]. It is one of the major causes of adult mortality and
morbidity. Thus, there is an urgent need to develop strategies to
improve the diabetes management and glycemic control. Vitamin A
is an essential micronutrient [2]. Deﬁciency in vitamin An uptake is
widely prevalent in developing countries and is possibly one of the
major causes of fetal growth restriction, and subsequent risk oftreptozotocin; T1DM, type 1
h factor-A; RAR, retinoic acid
r, Academia Sinica, Nankang,
, National Taiwan University,
), cnshen@gate.sinica.edu.twinsulin resistance and glucose intolerance in adulthood [3]. Recent
accumulating evidences suggest that vitamin A is a potent regulator
of metabolism and alterations in vitamin A status contribute to the
pathogenesis of obesity and diabetes [4]. This has increased the
interest in developing pharmacological strategies for controlling
the energy balance through natural and synthetic vitamin A de-
rivatives [5].
The majority of type 1 diabetes mellitus (T1DM) is of the
immune-mediated type in which the b-cell loss results from the T-
cell mediated autoimmune attack [6]. Vitamin A is an essential
component for maintaining immune tolerance and T-cell-mediated
immunity [7,8]. Therefore, impaired vitamin A metabolism can
affect the autoimmune response and development of T1DM [9].
Several clinical studies showed that the individuals with T1D had
decreased circulating levels of vitamin A or RBP4 as compared to
the non-diabetics [10e12]. Similarly, experimental models of T1DM
in rodents have also shown that the development of diabetes is
associated with a defect in vitamin A metabolism. For example,
serum vitamin A and hepatic levels of retinyl-palmitate (RP) were
signiﬁcantly decreased in streptozotocin (STZ)-induced diabetic
Fig. 1. AtRA treatment ameliorated glycemic control in the STZ-induced diabetic
mice. Non-diabetic (control) and STZ-induced diabetic CD-1 mice were treated with or
without 1 mg/kg atRA every other day. (A) Fasting blood glucose levels of mice in
control, STZ, and STZ þ atRA groups were determined on day 0, 2, 6, and 10. Values are
mean ± SEM. **p < 0.01 and ***p < 0.005 indicate statistically signiﬁcant differences as
compared to the STZ-treated group. (B) Plasma insulin levels of mice in control, STZ,
and STZ þ atRA groups were determined on day 10. Values are mean ± standard error
per group. **p < 0.01 indicates that the difference was statistically signiﬁcant as
compared to the STZ-treated mice. (C) The pancreas of control, STZ-treated, and STZ/
atRA-treated mice was immunostained with anti-Pdx1 (green) and anti-insulin (red)
antibodies. Nuclei were counterstained with Hoechst dye (blue). Scale bar, 50 mm. (D)
The amount of Pdx1-positive cells and (E) Pdx1/insulin-double positive cells in an islet
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metabolic availability of Vitamin A affects development of diabetes.
Vitamin A-rich foods have the potential of reducing the onset of
autoimmune diabetes [15]. For example, it was shown that vitamin
A deﬁciency caused hyperglycemia, loss of b-cell mass, and
impairment in glucose-stimulated insulin secretion (GSIS); how-
ever, repletion with the biologically active metabolite of vitamin A,
all-trans retinoic acid (atRA), restored GSIS and b-cell mass [16,17].
AtRA has been shown to possess the capability to enhance insulin
secretion and insulin content in the pancreatic b cells [18]. There-
fore, the current study aimed to evaluate whether treatment with
atRA can ameliorate diabetes. We examined if atRA administration
can improve glycemic control in STZ-induced diabetic mice and
evaluate whether treatment with atRA can enhance grafted islet
survival and function.
2. Material and methods
2.1. Reagents
All-trans retinoic acid (atRA) and streptozotocin (STZ) were
purchased from Sigma (St. Louis, MO). VEGF-A was obtained from
R&D System Inc. (Minneapolis, MN). AtRA, was dissolved in DMSO
(Sigma) and added to the islet tissue culture at the concentrations
indicated in the text.
2.2. Animal experiments
All animal experiments were approved by Academia Sinica
Institutional Animal Care and Utilization Committee. Mice were
housed under speciﬁc pathogen free conditions. Male CD-1 mice
(6e8 week old) were purchased from BioLASCO Taiwan Co., Ltd.
Diabetes was induced by ﬁve continuous injections of 40 mg/kg/
day STZ. In some experiments, diabetic mice were intraperitoneally
administered 1 mg/kg atRA every other day.
2.3. Immunoﬂuorescence staining
The pancreatic tissues were dissected and ﬁxed in 4% para-
formaldehyde overnight at 4 C. Tissue sections were rehydrated
through a graded alcohol series, pretreated with sodium citrate
antigen retrieval buffer (10 mM, pH 6.0), permeabilized with 1%
(vol/vol) Triton X-100 (in PBS), and incubated in 2% blocking buffer
(Roche) containing 0.1% Triton X-100, respectively. The tissue sec-
tions were then incubated with primary antibodies overnight at
4 C followed by incubation with secondary antibodies (supple-
mentary information) for 2 h in the dark at 25 C. Subsequently, the
tissue sections were mounted in Prolong Gold anti-fade reagent
(Molecular Probes, Eugene, OR).
2.4. Pancreatic islet isolation
The pancreatic islets of 6e8 week old male CD-1 mice were
isolated using collagenase P digestion, as previously described [19],
and cultured in RPMI 1640 medium containing 11.1 mM glucose,
100 units/mL penicillin, 100 mg/mL streptomycin, and 10% FCS
(Invitrogen, Carlsbad, CA). AtRA (1 mM) and anti-integrina6were calculated. Values are presented as percentage of the total insulin-positive cells in
an islet and expressed as mean ± SD. ***p < 0.005 indicates statistically signiﬁcant
difference as compared to the STZ-treated mice. (F) The pancreas of control, STZ-
treated, and STZ/atRA-treated mice was immunostained with anti-RAR (green) and
anti-insulin (red) antibodies. Nuclei were counterstained with Hoechst dye (blue).
Scale bar, 50 mm.
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second day of culture. All experiments were performed under low-
light conditions to avoid retinoid photoisomerization.
2.5. Insulin and VEGF-A secretion assays
The blood samples were collected in heparinized tubes by car-
diac puncture at the end of the experiment. The blood was
centrifuged at 1500 g for 10 min at 25 C, and the obtained plasma
was aliquoted and stored immediately at 20 C until assayed. All
samples were thawed at 4 C at the time of the enzyme-linked
immunosorbent assay (ELISA) analysis. Plasma VEGF production
was measured using VEGF-A ELISA kit according to the manufac-
turer’s instructions (Raybiotech, Norcross, GA). Measurement of the
plasma insulin was carried out with a mouse insulin ELISA kit ac-
cording to the manufacturer’s instructions (Mercodia, Uppsala,
Sweden).
2.6. Measurement of insulin content
For each independent experiment, 10 islets were plated and
exposed to the treatment conditions. Brieﬂy, the islets were lysed in
protein lysis buffer and the amount of whole islet protein was
measured by BCA protein assay. The insulin content was deter-
mined with mouse insulin ELISA kit (Mercodia) and normalized to
the total protein content.
2.7. Islet transplantation
After STZ treatment, the diabetic mice (blood glucose levels
>350 mg/dL) were randomly assigned to three groups and were
transplanted with islet mass (200 islets). At the time of trans-
plantation, mice were anaesthetized with Avertin (tri-
bromoethanol). A breach was made in the kidney capsule, and a
polyethylene catheter was introduced through the breach along the
kidney capsule to generate a subcapsular space. Freshly isolated
islets were then injected through the catheter into the subcapsularFig. 2. AtRA enhanced islet vascularization in diabetic mice. STZ-induced diabetic CD-1 m
treated and STZ/atRA-treated mice was collected on day 10, immunostained with anti-CD31 (
antibodies. Nuclei were counterstained with Hoechst dye (blue). Scale bar, 50 mm. The vascu
MetaMorph software. The percentage of CD31-positive area (A) and laminin-positive area in
area in an islet and expressed as mean ± SD. *p < 0.05 indicates statistically signiﬁcant diffe
STZ þ atRA mice groups were determined on day 10. Values are mean ± standard error ofspace and implanted beneath the renal capsule on the dorsal side of
the left kidney. After removing the catheter, the opening was
cauterized, and the kidney was repositioned, followed by suturing
of the muscles and skin [20,21]. At the end of the experiment, the
graft-containing kidneys were removed and ﬁxed in 10% (vol/vol)
buffered formalin, dehydrated, and embedded in parafﬁn.
Embedded tissues were consecutively sectioned at 5-mm thickness.
2.8. Determination of pancreatic Pdx-1, insulin, CD31 and laminin
expression pattern
Pancreatic Pdx-1, insulin, CD31 and laminin expression pattern
in the islets derived from each experimental groupwas determined
with double immunoﬂuorescence labeling. Images were captured
using a Zeiss or Leica Confocal Microscope and analyzed by Meta-
phorph software (Universal Imaging, Downingtown, PA).
2.9. Statistical analysis
Data are presented as the mean ± standard deviation (SD).
Statistical analysis was performed using Student’s t-test or one-way
ANOVA followed by post hoc Bonferroni’smultiple comparison test,
as appropriate, using GraphPad Prism software. Differences were
considered statistically signiﬁcant at p < 0.05.
3. Results
3.1. AtRA administration ameliorates the blood glucose level of
diabetic mice
Diabetes was induced in CD-1 mice by administering multiple
low-doses of STZ. Half of the diabetic mice were intraperitoneally
administered 1 mg/kg atRA every other day. Non STZ-treated/age
matched mice were used as control. The fasting blood glucose
level was determined every other day. The average fasting blood
glucose levels of control CD-1mice were below 150mg/dL (Fig. 1A).
After ﬁve continuous injections of STZ, the average fasting bloodice were treated with or without 1 mg/kg atRA every other day. The pancreas of STZ-
green) and anti-insulin (red) (AeB) or anti-laminin (green) and anti-insulin (red) (CeD)
lar areas that stained positively for CD31 (A) or laminin (C) were determined by using
an islet was calculated. Values are presented as percentage of the total laminin-positive
rence as compared to the STZ-treated mice. (E) Plasma VEGF levels of control, STZ, and
each experimental group.
Fig. 3. AtRA treatment elevated laminin expression and VEGF-A production in is-
lets. Islets were isolated from 6 to 8 week old CD-1 mice and cultured in RPMI 1640
medium containing serum. Islets were then treated with or without 1 mM atRA for 3
days. (A) Subsequently, the culture medium was collected and the level of VEGF-A in
the medium was determined using VEGF165 ELISA kit. Values were normalized to the
total cell lysate proteins and presented as pg/mg total protein ±SD. *p < 0.05 indicates
statistically signiﬁcant difference as compared to the untreated control islet culture.
(BeD) Immunoﬂuorescent staining was performed on the pancreatic islets treated
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treated mice were then divided into two groups; one group was
treatedwith atRA. After 10 days, the atRA-treated diabetic mice had
signiﬁcantly lower fasting blood glucose levels than the STZ-treated
diabetic mice had (average fasting glucose level >500 mg/dL). In
order to validate the effect of atRA treatment, plasma concentra-
tions of insulin were measured. The atRA-treated diabetic mice
showed higher levels of plasma insulin than the STZ-treated dia-
betic mice did (Fig. 1B). This explains why the atRA treatment can
improve glycemic control. Immunoﬂuorescent staining showed
that the atRA treatment partially restored insulin and Pdx1 ex-
pressions in the injured islet of the STZ-treatedmice (Fig. 1C and D).
Identiﬁcation of islet cells co-expressing Pdx1 and insulin indicated
that atRA treatment could possibly enhance b-cell regeneration in
diabetic mice (Fig. 1C and E). Furthermore, the expression of nu-
clear RARs was determined to evaluatewhether atRA treatment can
activate retinoic acid receptor (RAR) signaling in the islets of dia-
betic mice. The atRA-treated group showed higher levels of nuclear
RARs than the control group and STZ-treated group did (Fig. 1F).
The results suggested enhancement of b-cell regeneration in islets
of diabetic mice by atRA treatment is possibly mediated by acti-
vated RAR signaling.3.2. AtRA enhances islet vascularization in diabetic mice
Previous work demonstrated pancreatic islet production of
vascular endothelial growth factor-A (VEGF-A) regulates islet
vascularity and, consequently, affect the amount of insulin deliv-
ered into the circulation [20]. We therefore hypothesized that atRA
could improve hyperglycemia through enhance islet vasculariza-
tion. To assess the islet vascularization, expression of CD31 antigen
and vascular laminin in the islets of STZ-treated mice were deter-
mined using immunoﬂuorescent staining. STZ treatment not only
caused islet damage, but also signiﬁcantly reduced the levels of
CD31 antigen and vascular laminin (Fig. 2). In contrast, treatment
with atRA restored the levels of CD31 antigen and vascular laminin
in STZ-induced diabetic mice (Fig. 2AeD). Quantitative analysis
revealed that atRA treatment signiﬁcantly increased the percentage
of CD31 and laminin-expressing areas in the islets of the diabetic
mice (Fig. 2A and C). Since atRA treatment restored the islet
vascularity, its effect on the plasma levels of VEGF-Awas evaluated.
As shown in Fig. 2E, treatment with atRA increased the levels of
circulating VEGF-A.3.3. AtRA elevates vascular endothelial growth factor production in
islets
To validate whether atRA can regulate the pancreatic islet pro-
duction of VEGF-A, islets were isolated from 6 to 8 week old mice,
and cultured inmediumwith orwithout addition of 1 mM atRA for 3
days. Subsequently, the medium was collected and the level of
VEGF-A in the medium was determined. As shown in Fig. 3A, thewith or without atRA for laminin (C, green) or insulin (D, red). Cell nuclei were stained
with Hoechst dye (blue). Scale bar, 50 mm (B) Vascular areas that stained positively for
laminin in (C) were determined using MetaMorph software. The percentage of
laminin-positive area in the islets was calculated. Values are presented as percentage
of total laminin-positive area in an islet and expressed as mean ± SD. *p < 0.05 in-
dicates statistically signiﬁcant differences as compared to the untreated control islet
culture. (E) The total insulin content of islets treated with or without 1 mM atRA for 3
days was determined using insulin ELISA kit. Values were normalized to the total cell
lysate protein and presented as ng/mg total protein ±SD. ***p < 0.005 indicates sta-
tistically signiﬁcant difference as compared to the untreated control islet culture. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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cantly increased (by 36%) in the atRA-treated group (Fig. 3A). This
increase was accompanied by an enhanced laminin production
(Fig. 3B and C) and insulin levels (Fig. 3D and E). Next, we validated
whether the atRA-induced upregulation of laminin is the key factor
that increases insulin content in the islets. For this purpose,
laminin-integrin interactions were blocked by addition of
neutralizing anti-integrina6 antibodies to the islet cultures. This
signiﬁcantly inhibited the atRA-induced upregulation of laminin
expression and insulin content (Supplementary Fig. 1AeD). The
average insulin content in the control islets was 3418 ± 306.6 ng/
mg protein after 3-day culture. The insulin content in the atRA-
treated islets was 4402 ± 405 ng/mg protein (29% increase as
compared to the control islets) (Fig. 3E). In contrast, addition of the
neutralizing antibodies against integrin a6 downregulated the in-
sulin content to 3639 ± 123.8 ng/mg protein (Supplementary
Fig. 1D).3.4. AtRA improves islet graft vascularization and ameliorates
hyperglycemia in diabetic mice
To further analyze the beneﬁcial effect of atRA treatment on
glycemic control, STZ-induced diabetic mice were transplanted
with 200 islets. Half of the islet-transplanted diabetic mice were
treated with atRA every other day (STZ w/islet þ atRA group).
Fasting blood glucose levels of each experimental group were
measured on day 0, 4, and 10 post islet transplantation. The blood
glucose levels of diabetic mice that received islet transplantationFig. 4. AtRA improved islet graft vascularization and ameliorated hyperglycemia in diab
experimental groups (STZ w/islet, STZ w/islet þ atRA), each STZ-induced diabetic mouse w
administered with 1 mg/kg atRA every other day (STZ w/islet þ atRA group). (A) Fasting bloo
measured on day 0, 4, and 10 post islet transplantation. Values are mean ± SEM. ***p < 0.00
plasma insulin and VEGF-A levels of all experimental groups (STZ, STZ w/islet, STZ w/islet þ a
and **p < 0.01 indicate statistically signiﬁcant differences as compared to the atRA-treated
recipient mice were collected 10 days post-transplantation and immunostained with anti-
Hoechst dye (blue).and atRA treatment were restored to the normal range (123.67 mg/
dL) on day 4 (Fig. 4A). In contrast, the diabetic animals that received
only islet transplantation still suffered from moderate hypergly-
cemia (353.5e328.25 mg/dL) (Fig. 4A). To examine whether atRA
improves functional performance of islet grafts, the plasma levels of
insulin were determined after glucose injection at 10 days post-
islet transplantation. In response to the glucose challenge, signiﬁ-
cantly higher levels of plasma insulin (3.17 folds) were detected in
diabetic mice that received islet transplantation and atRA treat-
ment than in the corn oil-treated diabetic mice (2.09 vs. 0.66 mg/L;
p < 0.05) (Fig. 4B). The plasma levels of VEGF-Awere determined to
validate whether atRA treatment also enhances the VEGF-A pro-
duction in the islet-transplanted diabetic mice. The plasma VEGF-A
levels in the diabetic mice that received islet transplantation and
atRA treatment were higher than in the STZ-only group diabetic
mice (147.43 vs. 24.32 pg./mL) (Fig. 4C). Furthermore, atRA treat-
ment improved the grafted islet functionality and vascularity as
shown by the enhanced expression of C-peptide and laminin (Fig
4D and E).4. Discussion
This study showed that the atRA-induced upregulation of VEGF-
A produced by the islets mediated the restoration of islet vascu-
larity and recovery of bcell mass. Combination of islet trans-
plantation and atRA administration signiﬁcantly rescued
hyperglycemia in diabetic mice. These ﬁndings provide evidence to
support the idea that vitamin A derivatives can be used as aetic mice. STZ-induced diabetic mice were randomly divided into three groups. In two
as transplanted with 200 islets. Half of the islet-transplanted diabetic mice were also
d glucose levels of each experimental group (STZ, STZ w/islet, STZ w/islet þ atRA) were
5 indicates statistically signiﬁcant difference between the compared groups. (BeC) The
tRA) were determined on day 10. Values are mean ± standard error per group. *p < 0.05
groups. (D, E) The kidney islet grafts of corn-oil treated (D) or atRA-treated (E) diabetic
C-peptide (red) and anti-Laminin (green) antibodies. Nuclei were counterstained with
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glycemic control.
Several previous studies showed that both islet development
and maintenance of islet survival after transplantation require
signals produced by the endothelial microenvironment [22,23]. In
fact, proper vessel formation is a necessary step for generating
functional islets [24,25]. Among matrix components and vascular
factors produced by the endothelial microenvironment, laminin
can stimulate integrin a6b1 to promote b cell differentiation and
upregulate the insulin gene expression [26]. In the current study,
expression of vascular laminin increased after atRA treatment in
the STZ-induced diabetic mice (Supplementary Fig. 1AeB) sug-
gesting that atRA treatment activates laminin-integrin interaction.
Addition of neutralizing antibodies against intergrina6 inhibited
the atRA-triggered increase in the insulin content of the islet cul-
tures (Supplementary Fig. 1CeD). These results indicate that atRA-
mediated enhancement in the laminin expression has a potential
role in promoting b-cell differentiation and upregulating the insulin
gene expression in the residual b-cells of diabetic mice.
Previous studies using bovine aortic endothelial cells or human
umbilical vein endothelial cells demonstrated that atRA and RAR
agonists signiﬁcantly enhanced neovascularization [27e29]. This
suggests that retinoids can regulate angiogenesis. In this study,
atRA treatment upregulated the plasma levels of VEGF-A in the
STZ-induced diabetic mice. Moreover, using isolated islets, we
validated that atRA can upregulate the VEGF production from islets.
Pancreatic islets are highly vascularized and are known to express
VEGF-A [22,26]. Furthermore, the development of microvascula-
ture occurs concomitantly with islet neogenesis [29]. VEGF-A is a
major regulator of the islet vascularization during pancreatic
development. Inhibition of VEGF-A expression not only suppresses
the pancreatic b cell proliferation and insulin expression, but also
impairs the glucose-stimulated insulin secretion [24]. The islet
transplantation is a suitable therapeutic option in cases of failure of
pancreatic b cells to secret insulin, as in diabetes. For successful
transplantation, islets must receive enough nutritional and physical
support from the host through the formation of new blood vessels
around and within the graft to restore islet function. However,
isolated islets lose their natural vasculature and specialized extra-
cellular matrix [30]. Furthermore, the density of newly formed
vessels after transplantation is much lower than that in the native
islets [31]. Therefore, factors modulating the islet vascularity may
regulate the survival and function of the grafted islets. In the cur-
rent study, combined islet transplantation and atRA treatment
showed improvement in glycemic control. Importantly, atRA
treatment improved the functionality and vascularity of the grafted
islets. Taken together, the ﬁndings of this study imply that vitamin
A derivatives can be used as a supplementary treatment to improve
diabetes management and glycemic control.
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